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Summary We have used flow cytometry to study the mechanism of cytotoxic action of a series of ammine/
amine Pt(IV) dicarboxylates [ammine diacetatodichloro(cyclohexylamine) platinum(IV), JM216; ammine
dibutyratodichloro(cyclohexylamine)platinum(IV), JM221; ammine diacetatodichloro(propylamine)platinum-
(IV), JM223; ammine dibenzoatodichloro(propylamine)platinum(IV), JM244]. JM216 has been shown to have
clinical potential and has recently entered phase II trials. All the compounds caused a slowdown in S-phase
transit followed by a block in G2. Cells died either through apoptosis (largely during S-phase) or by failing to
overcome the G2 block (some days after treatment). In G2, the cells either divided or enlarged and died. At
equitoxic doses, JM216 showed the most apoptotic cells and had the most platinum bound to the DNA; JM244
showed the fewest apoptotic cells and had the least platinum bound to DNA. We suggest that whether
apoptosis was triggered or not was governed by the total amount of Pt bound to the DNA; the type of lesion
was more important in determining whether a cell became blocked in G2.
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Cis-dichlorodiammineplatinum(II) (cisplatin) is of major
importance in the treatment of cancer, particularly ovarian
and testicular carcinomas (Loeher and Einhorn, 1984;
Wiltshaw and Carr, 1984). Unfortunately, its value is limited
by its toxicity and the frequency with which tumours develop
resistance. While the side-effects of cisplatin have been
circumvented by the development of carboplatin, both drugs
show a similar pattern of resistance in a wide range of
tumours (Harrap, 1985; Gore et al., 1989; Mangioni et al.,
1989). The search for a third-generation platinum compound,
which does not show cross-reactivity with cisplatin and
carboplatin, has led to the development of a series of
platinum(IV) ammine/amine dicarboxylates of general
structure, c, t, c-[PtC12(OCORI)2NH3(RNH2)] (Harrap et
al., 1991a,b; Kelland et al., 1992a). One of these new
compounds [ammine diacetatodichloro (cyclohexylamine)-
platinum(IV), JM216], which has been shown to have
clinical potential (Kelland et al., 1993), has recently entered
phase II trials.
In human ovarian cell lines, it has been shown that the
cytotoxicity could be increased by increasing the number of
carbons in the carboxylate ligand (RI); cytotoxicity was also
increased by placing an alicyclic group in the amine ligand
(Kelland et al., 1992a). Two of the dicarboxylates [ammine
dibutyratodichloro(cyclohexylamine)platinum(IV), JM221;
and ammine dibenzoatodichloro(propylamine)platinum(IV),
JM244] were capable of overcoming acquired cisplatin
resistance, which is caused by decreased intracellular
accumulation but were not able to overcome resistance at
the level of DNA platination and removal (Kelland et al.,
1992b). The possible value of this class of compound in
overcoming cisplatin resistance has been supported by a
recent study of 17 ammine/amine Pt(IV) dicarboxylates using
the murine leukaemia cell line, L1210, and a cisplatin-
resistant subline in which it was found that a wide range of
these compounds overcame resistance to cisplatin (Orr et al.,
1994).
It is important to learn more about the mechanism of
action of the new compounds, particularly in relation to
cisplatin. Since attention has recently been focused on the
role of apoptosis in drug-induced cytotoxicity (Barry et al.,
1990; Dive and Hickman, 1991; Hickman, 1992), we have
investigated the contribution of apoptosis to cell killing by
cisplatin. In a human ovarian carcinoma cell line, CH 1,
cisplatin induced apoptosis over the whole dose range studied
(Ormerod et al., 1994b). In L1210 cells, the data were
consistent with a dual mechanism of cell death-higher doses
of drug led to rapid death through apoptosis; lower doses led
to death at later times resulting from a failure to overcome a
block in G2 of the cell cycle (Ormerod et al., 1994a).
As part of our programme of drug development, using the
murine leukaemia cell line, L1210, we have undertaken a
comparative study of the mechanism of toxic action of four
platinum(IV) ammine/amine dicarboxylates, namely, JM216,
JM221, ammine diacetatodichloro(propylamine)platinum(IV)
(JM223) and JM244 (for structures, see Table I). These
compounds were chosen as representative of the range of
compounds of this class, in that the amine contained either
an alicyclic (JM216 and JM221) or an alkyl (JM223 and
JM244) group and the axial ligand either an aryl (JM244) or
an alkyl substituent (JM216, JM221 and JM223). Flow
cytometry was used to follow changes in the cell cycle
parameters after incubation with drug and to measure the
induction of apoptosis.
Materials and methods
Chemicals
The Pt(IV) dicarboxylates were supplied by the Johnson
Matthey Technology Centre (Reading, Berks, UK) and the
Johnson Matthey Biomedical Research Center (West Chester,
PA, USA) (Giandomenico et al., 1991). Cell culture medium
and serum were purchased from ICN Flow (High Wycombe,
Bucks, UK), agar noble from Difco Laboratories (Detroit,
MI, USA) and all other reagents from Sigma (Poole, Dorset,
UK).
Cells and drug treatment
The L1210 murine leukaemia cell line was grown as a
suspension culture in RPMI-1640 medium supplemented with
10% horse serum, 2 mM L-glutamine and antibiotics
(100 U ml-' penicillin and 0.1 mg ml-' streptomycin) (cell
doubling time = 14 h).
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Table I Structures of four ammine/amine Pt(IV) dicarboxylates
Compound RI R2 IC50(YM) NH3 OCOR, C1
JM216 Methyl Cyclohexylamine 7.4NC
JM221 n-Propyl Cyclohexylamine 0.44 Pt
JM223 n-Propyl Isobutylamine 0.71 I
JM244 Phenyl Propylamine 0.065 2 OCOR1 Cl
IC50 for cisplatin =2.1gM
The Pt(IV) dicarboxylates were dissolved in ethanol, with
the exception of JM216 which was dissolved in unsupple-
mented medium. The final concentrations of ethanol (0.5%)
in the cultures did not inhibit growth over 48 h. All
experiments were initiated at a cell density of 2 x
105 ml-'. Following exposure to drug at different concentra-
tions for 2 h, cells were centrifuged at 800 g for 5 min,
washed once with medium and resuspended in fresh medium.
In cell survival assays, triplicate cultures of cells were
exposed to drug for 2 h, washed, resuspended in fresh
medium and serially diluted to 2 x 102 cells ml-'. Duplicate
aliquots (2 ml) were added to polystyrene tubes containing
3 ml of medium supplemented with 20% horse serum and
0.2% agar at 42°C. Tubes were plunged into iced water to set
the agar, incubated at 37°C for 7 days and colonies counted.
Plating efficiency of control cells was 78%. The concentration
of drug required to reduce colony formation by 50% (IC50)
was recorded.
Determination ofplatinum associated with whole cells and with
DNA
The Pt content of cell sonicates of extracted DNA was
measured by flameless atomic absorption spectroscopy as has
been fully described by Orr et al. (1994) and Nicholson et al.
(1992). The results were expressed as nmol Pt g-' protein or
nmol Pt g-' DNA.
Flow cytometry
Flow cytometric measurements were made either on an Ortho
Cytofluorograf 50H or a Coulter Elite ESP, both instruments
using Spectra-Physics argon-ion lasers tuned to produce
either 200 mW at 488 nm or 100 mW in the UV. On the
Cytofluorograf, data, normally from 2 x 104 cells, were
acquired and analysed on an Ortho 2150 computer system.
Univariate and bivariate histograms (the latter referred to as
cytograms) were transferred to an IBM compatible PC and
figures prepared using our own software (written by MGO).
For the figures, the frequency scale was adjusted to optimise
the display of the data. On the Elite, data were acquired on
an IBM-PC compatible computer. Figures were prepared
using the WINMDI program supplied by Dr Joe Trotter,
Salk Institute, USA.
On the Ortho Cytofluorograf, five detectors were available
recording, in a forward direction, scattered light and,
orthogonally, blue (488 nm, scattered light; or 460 nm,
fluorescence), and green (520 nm), orange (570 nm) and red
(>630 nm) fluorescences. A similar optical arrangement was
used on the Coulter. If the red fluorescence was measuring
DNA, then both the peak and the integrated area of the
fluorescent signal were recorded and pulse shape analysis was
performed to eliminate any cell clumps (Ormerod, 1994).
For cell cycle analysis, approximately 106 cells were fixed
in ice-cold 70% ethanol and stored at 4°C. After washing,
cells were resuspended in 800 ,l phosphate-buffered saline
(PBS) and 100 ,l propidium iodide (PI) solution
(100 Mg ml-') and 100 Ml RNAase solution (1 mg ml-')
added before incubation for 2 h at 37°C. The flow cytometer
was operated at 488 nm and, after pulse shape analysis and
gating on a cytogram of orthogonal vs forward light scatter,
either a histogram of cell number against red (DNA-PI)
fluorescence or a cytogram of light scatter vs DNA was
recorded. Cell cycle analysis was carried out using either our
own program (data recorded on the Cytofluorograf; Ormerod
et al., 1987) or the MultiCycle program (Phoenix Flow
Systems, San Diego, CA, USA) (data recorded on the Elite).
The fraction of apoptotic cells was estimated from the
'sub-GI' peak in the DNA histogram. If apoptotic cells
undergo internucleosomal degradation, on fixation, the cells
lose low molecular weight DNA and give a peak in the DNA
histogram of lower fluorescence than cells in GI of the cell
cycle (see, for example, Nicoletti et al., 1991; Ormerod et al.,
1992; Darnzynkiewicz et al., 1993). We have shown
previously that apoptotic L1210 cells undergo internucleoso-
mal degradation and produce such a peak in the DNA
histogram (Ormerod et al., 1994a). The fixed apoptotic L1210
cells also had smaller light scatter and the analysis could be
improved by setting a region on a cytogram of right angle
light scatter vs DNA.
To measure cell cycle progression, 50 ,UM bromodeoxyur-
idine (BrdUrd) was added to the cultures. Samples were
taken at different times, the cells centrifuged and resuspended
in ice-cold 100 mM Tris-HCl, 154 mm sodium chloride, 1 mM
calcium chloride, 0.5 mM magnesium chloride, 0.1% (v/v)
Nonidet-P40, 0.2% (w/v) bovine serum albumin, 1.2 ,ug ml-'
Hoechst 33258, pH 7.4; PI was added to a final concentration
of 2 ,ug ml- (Poot and Ormerod, 1994). UV radiation was
used for the flow cytometric analysis, which was performed
on the Ortho Cytofluorograf. After gating on a cytogram of
peak vs area of the red fluorescent (PI-DNA) signal, a
cytogram of red vs blue (Hoechst-DNA) fluorescence was
recorded.
Results
Cell survival
The survival of L1210 cells, as measured in a soft agar colony
assay, after incubation with the four compounds for 2 h is
shown in Figure 1. The values of the IC50s together with the
structures of the compounds are given in Table I. The
concentration of drug needed to achieve the same level of
cytotoxicity varied by a factor of 100-JM216 requiring the
most drug, JM244 the least.
Platinum uptake and platination of DNA
Table II shows the amount ofplatinum associated with DNA
and with the cells after a 2 h incubation with the four drugs
at 10 x IC50. There was significantly more Pt bound to DNA
after treatment with JM216 compared with JM244 but the
difference, which was reflected in the amount of intracellular
Pt, was less than 3-fold. There was a smaller, but also
significant, difference between JM216 and JM221.
Cell cycle analysis offixed cells
After a 2 h incubation with the four compounds, cells were
collected at different times, fixed in ethanol, stained with PI
and their DNA histograms analysed (Figure 2). At 10 x IC50,
by 6 h after treatment with JM216, there was substantial
apoptosis, the apoptotic cells giving a cluster with less DNA
('sub-GI' peak) and lower light scatter. Although apoptosisApoptosis and cell death by Pt(IV) dicarboxylates
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could be detected after incubation with 10 x IC50 of other
drugs, there were significantly less apoptotic cells present
(Figure 3). For all four drugs, at 3 x IC50, no apoptosis could
be detected (Figure 3 for JM216, data not shown for the
other drugs). The cells that did not die during the first 24 h
underwent a G2 delay, as is demonstrated in a plot of the
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Figure 1 Cell survival of L1210 cells following a 2h exposure to
JM216 (A), JM221(*), JM223 (U) or JM244 (0). Survival was
measured by a soft agar colony assay and the determinations were
performed in triplicate. The error bars represent+the standard
deviation and are shown when they are larger than the symbols.
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fraction in each phase of the cell cycle vs time (Figure 4). By
24 h, the arrested cells showed increased light scatter,
presumably caused by an increase in cell size, as has been
observed after incubation with cisplatin (Sorenson et al.,
1990; Ormerod et al., 1994a). By 48 h, cycling cells of normal
light scatter were again evident. The cell cycle effects after
incubation with the drugs at 3 x IC50 were similar, but less
marked, to those at 10 x IC50 (data not shown).
Table II The amount of Pt associated with the cells and the
amount bound to DNA after a 2h incubation of L1210 cells with
four ammine/amine Pt(IV) dicarboxylates
Drug nmol Ptg-l protein nmol Ptg-1 DNA
JM216 840665 65+ 16
JM221 378406 31+8
JM223 333400 37+27
JM244 237307 24+9
The dose of drug was 1O x IC50 in each case. The results of two
measurements are shown for Pt associated with the cells. Standard
deviations are shown for Pt bound to DNA (n=3). The amount of
platinum bound to DNA after incubation with JM216 was
significantly higher than that bound after incubation with JM244
(P<0.05). The amount of platinum associated with the cells after
incubation with JM216 was significantly higher than that associated
after incubation with either JM221 or JM244 (P<0.05). All other
comparisons showed no significant difference (P>0.05).
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Figure 2 Flow cytometric cytograms (RALS against PI/DNA red fluorescence) of L1210 cells at different times after a 2h
incubation with Pt(IV) compounds at 10 x IC50. The numbers on the top of the Figure represent the time in h. The positions of cells
in GI, G2 and apoptotic cells (Ap) are marked on the DNA axis. The cells were fixed in 70% ethanol and, after rehydration, stained
with PI. Coulter Elite, 488 nm excitation.
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Although there was some variation between experiments in
the percentage of apoptotic cells observed after a given dose
of drug, it was consistently observed that, at equitoxic doses,
the percentage of apoptotic cells followed the progression
JM216>JM221 JM223 >JM244.
Cell cycle progression
0 10 20 30
Time (h)
Figure 3 The fraction ofapoptotic cells in culture
at different times after a 2h incubation wit]
JM221(*), JM223(0) or JM244(A) at 10 xIC50
at 3 x IC50. The fraction of apoptotic cells was ob
'sub-GI' peak shown in Figure 2.
80 _-
Progression of cells through the cycle was followed by
incubating the cells continuously in BrdUrd after a 2 h
incubation with drug. Permeabilised cells were stained with
the DNA-binding dyes, Hoechst 33342 and PI. The red
fluorescence (DNA-PI) identified the cell cycle compartment,
40 50 while the blue fluorescence (DNA-Hoechst) was quenched by
BrdUrd and identified those cells which had taken up the
es of L1210 cells thymidine analogue (Rabinovitch et al., 1988). A detailed
h JM216 (0) description of the application of this method to asynchronous
or JM216 (x) cells has been given by Ormerod and Kubbies (1992), Poot
)tained from the and Ormerod (1994) and Ormerod (1994).
Figure 5 shows cytograms obtained from untreated cells.
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Figure 4 The percentage of cells in different phases of the cell cycle after no drug or after a 2 h exposure to JM216. JM221, JM223
or JM244 at 10 x IC50. The data were derived from three experiments; the error bars represent +the standard deviation. 0, GI; *,
S; and A, G2/M. The graphs show data from the surviving cells in the culture.
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vvAt time 0, GI-, S- and G2/M-phases of the cell cycle could be
identified from both the red (PI) and blue (Hoechst)
fluorescence. After 3 h in BrdUrd, cells originally in G2/M
had divided and moved into GI (unlabelled). Cells in S-phase
showed increasing red fluorescence with cell cycle progres-
sion, but no increase in blue fluorescence (quenched by the
BrdUrd) and reached the region labelled G2-. At 6 h, all the
cells now in S had been in GI at time 0 h (Sf on Figure 5);
some had progressed as far as G2/M (G2f) and divided again
(marked GI). Cells which had begun the experiment in S-
phase and had now reached GI are labelled GI.. At 9 h, there
were few cells which had not left GI. Cells which had
completed one cycle (G,) were clearly visible.
The effects of incubation with drug are illustrated at three
time points for JM244 at 10 x IC50 and 3 x IC50 (Figure 6).
Three hours after incubation with both doses of drug, the
major effect observed was a slowdown in movement of cells
through S-phase, while most of the cells in G2/M at the time
of treatment had divided. At 6 h, after 3 x IC50, some cells
from late S-phase had progressed back to GI (9% of the
total); cells treated in mid and early S-phase were held up in
late S/G2. By 9 h, most of the cells which had been in G, and
G2/M at time 0 had progressed into S (Se), some had reached
G2 and become blocked there (G2t). Most cells treated in mid
No
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and late S-phase had overcome any G2 block and divided.
(Cells treated in S-phase, which had become blocked in G2,
would have been to the right of the position marked G2* in
Figure 6). After 10 x IC50, the same pattern was observed, but
the general slowdown in cell cycle progression was even more
marked. After 9 h, cells from G1 and early S had still to reach
G2.
Incubation with the other drugs at 3 x and 10 x IC50 gave
similar results, except that apoptotic cells were evident after
the higher concentration of drug (Figure 7). The number of
apoptotic cells observed was greatest with JM216 and least
with JM244.
The BrdUrd-Hoechst/PI method was also used to explore
the fate ofcells, which became blocked in G2 (Figure 8). Cells
were incubated with 10 x IC50 JM221 for 2 h, washed, and
either BrdUrd was added immediately or they were incubated
for a further 24 h, when BrdUrd was added. Incubation with
BrdUrd for 24 h showed that the large majority of the cells in
G2 were cells that had been exposed to the drug in GI or G2/
M of the cell cycle (G2f in Figure 8). Most of the cells in G,
had divided during the previous 24 h (G1). Addition of
BrdUrd 24 h after incubation with drug showed that there
were two populations ofcells, one cycling normally, the other
blocked in G2 and disappearing from the culture. The
Blue (Hoechst) fluorescence
Figure 5 L1210 cells incubated continuously with BrdUrd. Cytograms of red (PI-DNA) vs blue (Hoechst-DNA) fluorescence after
staining permeabilised cells with Hoechst 33352 and PI. The cell cycle phases are marked. G2f marks those cells in G2/M which were
in S-phase at the time of addition of BrdUrd; Sf, cells which were initially in GI and had moved into S-phase; G., cells which were
initially in S-phase and had divided and were in GI; G1, cells which were initially in G, and had cycled through to G, after addition
of BrdUrd and S and G2 are cells in their second cycle. The numbers on the cytograms give the time in h after addition of BrdUrd.
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normally cycling cells are in the compartment marked G,,
G,, G2f and G2 in the two bottom panels in Figure 8. After a
total of 48 h (24 h with BrdUrd), the cells blocked in G2 had
3 x IC50
G2*
3
V~~~~~~~~
U)~ ~ ~~~S
-U a)
almost completely disappeared from the culture. If they had
divided, there would have been cells in the compartment, GI,
so it can be concluded that these cells had died.
10 x IC50
Blue (Hoechst) fluorescencs
Figure 6 L1210 cells incubated continuously with BrdUrd after a 2h incubation with JM244 at lOx IC50. Cytograms of red (Pl-
DNA) vs blue (Hoechst-DNA) fluorescence after staining permeabilised cells with Hoechst 33352 and PI. The cell cycle phases are
marked according to the description given in Figure 5. The numbers on the cytograms give the time in h after addition of BrdUrd.
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A major feature of the survival data in Figure 1 was the large
differences in the concentration of drug needed to achieve the
same level of cytotoxicity. JM216 was used at 100 times the
concentration of JM244 with JM221 and JM223 lying in
between. A large part of the differences would have been
caused by differential uptake of the drugs by cells and by
3 x IC50
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their intracellular metabolism. When the reaction of the drug
with the cell, as measured by the amount of intracellular
platinum or the platinum bound to DNA, is measured at
equitoxic doses, the difference is only 3-fold. At equitoxic
doses, the platinum bound to the cell had the same
rank order as the concentration of drug added
(JM216>JM221 ~JM223 >JM244). The ratio of the
amount of Pt g protein to Pt g - DNA was approximately
10 X IC50
Blue (Hoechst) fluorescence
Figure 7 L1210 cells were incubated with JM216, 221 or 223 at a concentration equivalent to either 3 x IC50 or 10 x IC50 for 2h,
washed and then incubated with BrdUrd for 6h. Details as in Figure 5. Ap marks apoptotic nuclei.
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Figure 8 L1210 cells were incubated with JM221 at 10 x IC50 for 2 h and then either incubated continuously with BrdUrd for 24h
(upper left hand panel) or incubated for 24h before the addition of BrdUrd (other three panels). Cells were harvested after 3.5, 8 or
24h incubation with BrdUrd and analysed as in Figures 5-7. The numbers on the panels give the time of incubation without
BrdUrd followed by the time of incubation with BrdUrd. The cell cycle phases are marked according to the description given in
Figure 5.
the same for the four drugs (about 10), so that the rank order
held whichever measurement was used.
At doses of drug of 3 x IC50 for all four drugs or at
10 x IC50 for JM221, JM223 or JM244, the effects on the cell
cycle were similar to those observed with cisplatin (Sorenson
and Eastman, 1988a,b; Sorenson et al., 1990; Demarq et al.,
1992; Fujikane et al., 1989; Ormerod et al., 1994a). Initially,
there was a slowdown in transit through S-phase followed by
a G2 block. This conclusion can be drawn from both the
DNA histograms and the data acquired after incubation with
BrdUrd (Figure 6). The cells blocked in G2 enlarged (as
evidenced by their increased light scatter, Figure 2) before
eventually dying.
From our previous work, we have concluded that there are
two mechanisms whereby cisplatin kills cells (Ormerod et al.,
1994a,b, 1996). The earlier mechanism is apoptosis, which is
probably triggered while the cells are held up in S-phase. If
cells complete S-phase and if they fail to overcome the block
in G2, they die in the blocked G2 stage of the cell cycle,
probably by a non-apoptotic mechanism. In human ovarian
carcinoma cells, apoptosis predominated at doses of drug
>3 x IC,o (Ormerod et al., 1994b, 1996), whereas, in L1210
cells, apoptosis was only observed at doses of drug
> 15 x IC50 (Ormerod et al., 1994a).
The same mechanisms were observed in this study. With a
sufficiently high dose of any of the four drugs, apoptosis was
observed after 4-12 h. However, at equitoxic doses, the
number of apoptotic cells observed was ranked
JM216 >JM221
- JM223 >JM244; this was the same rank-
ing as the amount of Pt bound to the DNA. The induction of
apoptosis seemed to be related to the amount of damage to
DNA. The inability to overcome a G2 block might be more
closely related to the type of lesion.
While there have been several studies of the lesions caused
by the reaction of cisplatin with DNA (for example, see
Roberts and Friedlos, 1987; Eastman, 1987), little is known
about the reaction of the Pt(IV) dicarboxylates with the DNA
in cells. Indeed, it is probable that the metabolites of these
drugs react with the DNA rather than the parent compound
(Kelland et al., 1992). For example, it appears that iproplatin,
cis -dichloro - trans -dihydroxo -cis-bis(isopropylamine)Pt(IV),
undergoes reduction to a Pt(II) metabolite before reacting
with DNA in cells (Pendyala et al., 1990). In cultured human
ovarian carcinoma cells, metabolites of JM216 include
JM1 18 -cis-ammine dichloro (cyclohexylamine) Pt (II),
JM338 - bis-acetato ammine (cyclohexylamine) dihydroxo Pt
(IV)-and a glutathione adduct (Raynaud et al., 1996).
From our data, it would appear that JM244 is more
effective than JM216 in creating lesions on the DNA, which
block the cell in G2 of the cell cycle. At doses of drug
< 15 x IC50, this effect predominated. In contrast, because the
lesions created by JM216 were less effective at blocking the
cells in G2, at an equitoxic dose, sufficient DNA damage
accumulated to trigger apoptosis.
It would be interesting to study the effect of these drugs on
the human ovarian cell line, CH1. Cisplatin triggers apoptosis
in these cells at doses >3 x IC50. A comparative study of
JM216 and JM244 might reveal whether these cells are more
sensitive to the induction of apoptosis than L1210 cells or
whether they are more resistant to a G2 block.
Recently, attention has been focused on the role of
apoptosis in drug-induced cytotoxicty. The data presented
in this paper, taken together with our earlier data (Ormerod
et al., 1994a,b, 1996), suggest that, when mechanisms of
resistance are studied, other cytotoxic mechanisms should
also be taken into account.
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